In one paragraphArticle in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
14 authors.
Christian M BeuschPathology Advanced Translational Research Unit, Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA, USA.ORCID 0000-0001-9100-8283 Carolyn MorningstarPathology Advanced Translational Research Unit, Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA, USA.ORCID 0009-0004-4632-1587 Marc SemaanDepartment of Biochemistry and Cell Biology, Boston University Chobanian and Avedisian School of Medicine, Boston, MA 02118.ORCID 0000-0003-3828-9105 Christopher M MonacoPathology Advanced Translational Research Unit, Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA, USA.ORCID 0000-0001-7802-6188 Sarah WelbournPathology Advanced Translational Research Unit, Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA, USA.ORCID 0000-0002-2932-1436 Hailey SwaldiPathology Advanced Translational Research Unit, Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA, USA.ORCID 0009-0007-1099-6779 Jae-Kyun KoPathology Advanced Translational Research Unit, Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA, USA.
Devin KenneyDepartment of Biochemistry and Cell Biology, Boston University Chobanian and Avedisian School of Medicine, Boston, MA 02118.ORCID 0000-0002-8758-1930 David LiuDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Hisashi AkiyamaDepartment of Virology, Immunology and Microbiology, Boston University Chobanian and Avedisian School of Medicine, Boston, MA 02118.ORCID 0000-0001-9228-0465 Mohsan SaeedDepartment of Biochemistry and Cell Biology, Boston University Chobanian and Avedisian School of Medicine, Boston, MA 02118.ORCID 0000-0001-8505-7054 David E GordonPathology Advanced Translational Research Unit, Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA, USA.ORCID 0000-0001-7954-0306 Funding
Translational ScienceP30AI042853 · NIAID · MIRIAM HOSPITAL · PI CURT G BECKWITH, DEBBIE M. CHENG · 1998 to 2026
$51.7MRNA modification and innate immune activation in HIV infectionR01AI183400 · NIAID · BOSTON UNIVERSITY MEDICAL CAMPUS · PI Hisashi Akiyama · 2024 to 2026
$2.5MDefining the role of site-specific proteolysis in innate defense signalingR35GM147483 · NIGMS · BOSTON UNIVERSITY MEDICAL CAMPUS · PI Mohsan Saeed · 2022 to 2026
$2.1MInnate sensing of HIV in microgliaR21NS126092 · NINDS · BOSTON UNIVERSITY MEDICAL CAMPUS · PI AKIYAMA, HISASHI · 2021 to 2022
$465kNIAID NIH HHS P30 AI042853NIAID NIH HHS R01 AI183400NIGMS NIH HHS R35 GM147483NINDS NIH HHS R21 NS126092
6 · The paper itselfAbstract
Signaling networks modulated by post-translational modifications orchestrate cellular responses to external cues. Traditional approaches to study these pathways lack the throughput to systematically capture the causal architecture of these signaling pathways at scale. Here, we present an integrated proteogenomic framework that combines saturating genetic perturbations with high-throughput proteomics to systematically map cytokine-induced signaling in primary human T cells. Supporting this framework is
Identifiers
PMID41279008
PMCPMC12632528
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390